NEW YORK (GenomeWeb) – Neuropsychiatric molecular diagnostics firm Assurex today said that it has secured a $25 million credit facility and $7 million in investments.
The funds will be used to increase clinical adoption of the Mason, Ohio-based firm's GeneSight products.
AssureRx Launches GeneSightRx ADHD
AssureRx Health this week launched a pharmacogenetic test, called GeneSightRx ADHD, for characterizing patients' response to a variety of attention deficit hyperactivity disorder drugs.
By sequencing a pair of serotonin biosynthesis genes in hundreds of Norwegian individuals, researchers have identified mutations in mothers' serotonin genes that appear to bump up their children's chances of attention-deficit hyperactivity disorder symptoms.